Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …

Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts
and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide …

Durvalumab Combination for Biliary Tract Cancer This trial randomly assigned patients with
previously untreated locally advanced or metastatic biliary tract cancer to receive …

Background The gut microbiome is associated with the response to immunotherapy for
different cancers. However, the impact of the gut microbiome on hepatobiliary cancers …

Background HER2 is overexpressed or amplified in a subset of biliary tract cancer.
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …

PURPOSE SWOG S1815 was a randomized, open label phase III trial, evaluating
gemcitabine, nab-paclitaxel, and cisplatin (GAP) versus gemcitabine and cisplatin (GC) in …

Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report
the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin …

Metabolic reprogramming is a hallmark of cancer and allows tumour cells to meet the
increased energy demands required for rapid proliferation, invasion, and metastasis …

PURPOSE Whether triplet chemotherapy is superior to doublet chemotherapy in advanced
biliary tract cancer (BTC) is unknown. METHODS In this open-label, randomized phase II-III …